RichardJRodehefferMD
Cardiology • Rochester, MNAdult Congenital Heart Disease, Heart Failure & Transplantation
Professor of Medicine Mayo Clinic
Dr. Rodeheffer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Summary
- My focus is in clinical care and research in the area of heart failure and cardiac transplantation. On coming to Mayo Clinic in 1987, I co-founded our transplnat program and founded our Heart Failure Clinic.
Education & Training
Johns Hopkins UniversityFellowship, Cardiovascular Disease, 1982 - 1983- Johns Hopkins UniversityResidency, Internal Medicine, 1977 - 1981
University of Rochester School of Medicine and DentistryClass of 1977
Certifications & Licensure
WI State Medical License 2014 - 2025
MN State Medical License 1987 - 2024
TN State Medical License 1984 - 1987
MD State Medical License 1979 - 1985- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Prevalence of Asymptomatic Ventricular Dysfunction Start of enrollment: 1997 Jan 01
Publications & Presentations
PubMed
- 77 citationsSirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac TransplantationYan Topilsky, Tal Hasin, Eugenia Raichlin, Barry A. Boilson, John A. Schirger
Circulation. 2012-02-07 - 124 citationsConversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac TransplantationEugenia Raichlin, Jang Ho Bae, Zain Khalpey, Brooks S. Edwards, Walter K. Kremers
Circulation. 2007-12-04 - 355 citationsNatriuretic peptide system in human heart failure.Chi Ming Wei, Denise M. Heublein, Mark A. Perrella, Amir Lerman, Richard J. Rodeheffer
Circulation. 1993-09-01
Other
- Development of malignancy following solid organ transplantationRodeheffer RJ, Brennan DC, Ambinder RF
http://www.uptodate.com/contents/development-of-malignancy-following-solid-organ-transplantation
UpToDate, Wolters Kluwer Health - 2013-04-18
Authored Content
- Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
- Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
- Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
- Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
- Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
- Join now to see all
Press Mentions
Diabetes Kann Unabhängig Zu Herzinsuffizienz Führen, Wie Eine Bevölkerungsstudie ZeigtJanuary 6th, 2020- Selon Une Étude Portant Sur Une Population, Le Diabète Peut Entraîner Indépendamment Une Insuffisance CardiaqueJanuary 6th, 2020
Grant Support
- Prevalence Of Asymptomatic Ventricular DysfunctionNational Center For Research Resources2004–2005
- Prevalence Of Asymptomatic Ventricular DysfunctionNational Heart, Lung, And Blood Institute2004
- Prevalence Of Asymptomatic Ventricular DysfunctionNational Heart, Lung, And Blood Institute1997–2003
- Prevalence Of Asymptomatic Ventricular DysfunctionNational Center For Research Resources2000–2002
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
